RDNTRadNet demonstrates solid fundamental performance in the growing outpatient imaging sector, supported by technological advancements in AI. However, recent performance has been weak, and the stock shows bearish technical signals. Long-term investors may find value, but short-term caution is advised.
RadNet is well-positioned within the expanding healthcare services and diagnostic imaging market, with a clear focus on digital health and AI integration.
RadNet shows revenue growth, but profitability has been inconsistent, with recent negative EPS and fluctuating net margins. The company carries significant debt, although its cash position has improved.
The stock is trading below its key moving averages, showing bearish momentum and signals across multiple timeframes. Immediate price action suggests downward pressure.
| Factor | Score |
|---|---|
| Healthcare Services Growth | 85 |
| AI Integration in Radiology | 90 |
| Digital Health Adoption | 80 |
| Regulatory Landscape | 65 |
| Competitive Landscape | 75 |
| Factor | Score |
|---|---|
| Valuation | 55 |
| Profitability | 40 |
| Growth | 70 |
| Balance Sheet Health | 50 |
| Cash Flow | 60 |
| Earnings Per Share (EPS) | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 55 |
| Volume Confirmation | 65 |
| Support & Resistance | 75 |
| Short-term Oscillators | 60 |
Diversified Imaging and Digital Health Services
RadNet, Inc. offers a broad range of outpatient diagnostic imaging services and has a growing digital health segment, including AI solutions for radiology, suggesting a diversified and forward-looking business model.
Consistent Revenue Growth
Revenue has shown a consistent upward trend from $1.31 billion in 2021 to $1.83 billion in 2024, indicating increasing demand for its services.
Negative Net Income and Margins
The company has reported negative net income for TTM (-$29.4 million) and recent quarters (e.g., Q1 2025: -$37.9 million), with very thin or negative net margins, indicating profitability challenges.
Inconsistent and Negative EPS
EPS estimates and reported figures have been volatile and often negative, with a reported EPS of -0.35 in Q2 2025 against an estimate of -0.13, indicating significant earnings misses and unprofitability.
August 2025
8
Next Earnings Date
H: $0.23
A: $0.16
L: $0.10
H: 492.62M
A: 488.06M
L: 483.10M
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
71.57 USD
The 39 analysts offering 1 year price forecasts for RDNT have a max estimate of 80.00 and a min estimate of 60.00.